Speech by Federal Chancellor Olaf Scholz at the groundbreaking ceremony for the Translation Center for Cell and Gene Therapy on June 21, 2024, in Berlin:

Germany Olaf Scholz · Member of the Bundestag

21 June 2024 · Groundbreaking ceremony for the Translation Center for Cell and Gene Therapy · Berlin, Germany

Context
Scholz addressed the groundbreaking ceremony for the Translation Center for Cell and Gene Therapy at Charité Berlin on June 21, 2024, marking a major science-industry collaboration.
Main themes
Cell and gene therapy, Translation Center groundbreaking, Charité and Bayer AG collaboration, biomedical research and innovation, federal government funding, bridging basic research to clinical practice, cancer and genetic disease treatment, Germany as a science and pharma hub, pharmaceutical strategy and medical research law, Rudolf Virchow legacy, clinical trials and drug approval reform
Duration
~9 min
31st percentile
Words
1,068
31st percentile
Sentences
64
42nd percentile
Readability
54
75th percentile
Grade
9.7
17th percentile
Syntax
2.83
26th percentile
Vocabulary
2.05
17th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 32%31%
  • Economic 27%27%
  • Ceremonial 22%22%
  • Technological 14%14%
  • Institutional 5%5%
  • Geopolitical 0%0%
  • Environmental 0%0%
  • Not in focus 2%

64 sentences in 18 paragraphs

Ladies and gentlemen,

Rudolf Virchow was ahead of his time. He researched cells and wrote as early as the mid-19th century that "these small elements, the cells, are the actual foci of life and therefore also of disease." Without Rudolf Virchow, without his research on cells as the building blocks of all life, we might not be here today. Cancer, Parkinson's, autoimmune diseases, rare genetic disorders, all of them can be treated much better today than in Rudolf Virchow's time. Thanks to medicine and the biosciences, we know vastly more about our organism and how it functions.

And yet, some of the great questions that Rudolf Virchow posed still remain: How do some diseases arise, and, even more importantly, how can we prevent them? – Because there are still diseases that cannot be treated – we have already heard this – diseases for which there are no therapies or medications. This statement needs to sink in. Because being ill is one thing. But being incurably ill is something entirely different.

It is precisely here that the great potential of cell and gene therapies becomes evident, first and foremost for the patients, but also for the economy and for science. These therapies can cure diseases for which there is currently no treatment, or better yet, they can prevent such diseases from arising in the first place.

Right now, hundreds of clinical trials are underway to develop gene and cell therapies, and patients are already being treated with them at Charité. However, so far only a few products have been approved in Europe. This translation center can change that. You aim to start here in just three years. That is ambitious and impressive. It has been assured multiple times that it will succeed. I am watching!

Because what we are celebrating here today is not only the starting signal but also a unique form of collaboration between science, industry, and politics. With Charité, the largest university hospital in Europe is on board, an innovation driver not only in medical history – I have already mentioned Rudolf Virchow – but also in the present and future. Just think of the invention of the first effective coronavirus test or the cutting-edge research on human organ models being conducted here.

In addition, Bayer AG, a world-class pharmaceutical company, is involved. Bayer Leverkusen has deservedly become the German champion for the first time this year. Bayer is also a German champion, for example, in the production of pharmaceuticals. Bayer ranks high in research intensity as well. That is why your company is a great partner to translate the basic research of Charité directly into therapies, into therapies that help patients worldwide to recover or to stay healthy. Because that is exactly the gap we want to close with this center, from basic research to practice.

This translation is important. In basic research, we are traditionally at the top in Germany, but on the way to practice, we are occasionally still "lost in translation." We want to change that. This "we" also includes the state of Berlin and the federal government. It is clear: especially at the beginning, new technologies also need state support. That is why we are helping by providing around 80 million euros from the federal government for the construction of the manufacturing facility and for the establishment and development of the center.

At the same time, I am firmly convinced that this center will soon be economically viable as well. Because in the long run, meaningful technologies have always prevailed. In this case, they are even technologies that save or improve lives. That is a trend that endures through all time. The founder of the AI company DeepMind, Mustafa Suleyman, describes this in his book "The Coming Wave" as follows: "Almost every fundamental technology ever invented follows a single, seemingly unassailable law: It becomes cheaper and easier to use, and eventually finds widespread adoption."

I am quite sure: Cell and gene therapies will also continue on this path.

We invest more than three percent of our gross domestic product in research and development, more than all other major countries in Europe. This is also one reason why we are the third-largest economy in the world with only 84 million inhabitants: because we have research-intensive companies, because we have outstanding academic and non-university research institutions. Particularly in novel biotechnologies and mRNA technology, German research is internationally leading. Outstanding talents, a strong industrial base in the chemical and pharmaceutical industries, specialized suppliers in the mid-sized sector, and pronounced industry knowledge all characterize us.

At the same time, competition for locations has become tougher. That is why the federal government launched the pharmaceutical strategy at the end of 2023. A central component is the draft law for a medical research law, which will make clinical trials and drug approvals simpler and faster. An important law, the Health Data Utilization Act, came into force in March. It helps researchers gain better access to health data. When they have more data, they will be able to use it better, for example, to recognize correlations.

In recent weeks, I have visited many companies in the innovative healthcare sector. The feedback was clear. The pharmaceutical strategy and the laws mentioned are correct, and they are important. They are a reason to invest here in Germany, in research buildings, in high-tech production facilities, in new jobs.

So that these jobs can also be filled with the best people, we have significantly facilitated the immigration of skilled workers. You will hopefully soon feel this at Bayer and here at Charité in your daily work.

This translation center can thus become the core or, better said, the cell nucleus of an entire organism of gene and cell-based therapies, a second Boston, as it has often been called here – because there is already a similar center there – a Boston on the Spree, focusing on research. I have been to the city. It looks very different.

For this, we need scientists and entrepreneurs who can see both the smallest details in the cell nucleus and the big picture, namely the medicine of the future, which provides answers to the great questions that Rudolf Virchow already posed. It is good that we have both here in Germany, both courageous researchers and innovative entrepreneurs.

I wish you much success with this visionary project. You have my support for it.

Thank you very much.